Literature DB >> 3260900

Genetic characterization of human KB cell lines resistant to epidermal growth factor: Pseudomonas exotoxin conjugates.

F Amano1, I Pastan, M M Gottesman.   

Abstract

Pleiotropic human KB cell mutants, selected for resistance to a conjugate of epidermal growth factor with Pseudomonas exotoxin (PE-EGF), were characterized genetically. These mutants have a pleiotropic phenotype, which includes reduced number of EGF receptors and reduced growth rate. Hybrid cells between HeLa D98 and four out of five of these resistant cell lines were more resistant to PE-EGF than hybrids formed between HeLa D98 and parental KB cells. This result indicates that the phenotype of PE-EGF resistance is incompletely dominant in four out of five cases and recessive in one out of five variants. In three separate experiments, transfection of DNA from two of the dominant resistant cell lines resulted in transformation of wild-type KB cells to PE-EGF resistance, confirming the dominant nature of these mutations, which affect levels of EGF receptor in KB cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260900     DOI: 10.1002/jcp.1041350323

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.513


  3 in total

1.  Effects of 131I-EGF on cultured human glioma cells.

Authors:  J Capala; M Pråhl; S Scott-Robson; J Pontén; B Westermark; J Carlsson
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

2.  Mitogenic signaling pathways of growth factors can be distinguished by the involvement of pertussis toxin-sensitive guanosine triphosphate-binding protein and of protein kinase C.

Authors:  N Nishizawa; Y Okano; Y Chatani; F Amano; E Tanaka; H Nomoto; Y Nozawa; M Kohno
Journal:  Cell Regul       Date:  1990-09

3.  Effects of EGF-dextran-tyrosine-131I conjugates on the clonogenic survival of cultured glioma cells.

Authors:  A Andersson; J Capala; J Carlsson
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.